ADEPT-2 Study: KarXT for Psychosis in Alzheimer's Disease
This study is testing KarXT to see if it can help treat psychosis (hallucinations and delusions) in people with Alzheimer's disease. Researchers want to know if KarXT is safe and effective compared to a placebo (a pill with no medicine). You may be able to join if you are 55 to 90 years old, have mild to severe Alzheimer's disease, and experience moderate to severe psychosis. The study will measure changes in hallucinations and delusions to see how well KarXT works. The study plans to enroll about 500 participants, but its current status is unclear.
- Study design
- This is a Phase 3 study, meaning it's a later-stage trial. It's designed as a randomized, double-blind, placebo-controlled study, involving about 500 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome is measured up to 14 weeks after the start of treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
At a glance
Conditions
Where it's being run
154 sites across 61 statesStudy leadership
- Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change from Baseline to End of Treatment in the Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C: H+D) scoreBaseline and end of Treatment (up to 14 Weeks)
Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions scale includes 2 domains from the NPI-C scale, namely, hallucinations and delusions. These 2 domains include the following number of items to be rated by the clinician: Hallucinations, 7 items (maximum score = 21) and Delusions, 8 items (maximum score = 24). The maximum score for the NPI-C: H+D scale is 45. Higher scores on this scale indicate worse outcomes.